Clinical Trial Update: Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer [Phase 3]

View source ↗

Summary

This update reports on a Phase 3 study comparing bavituximab plus docetaxel versus docetaxel alone in late-stage non-squamous non-small cell lung cancer; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bavituximab (bavituximab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Peregrine Pharmaceuticals | Conditions: Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV | Phase 3 | Status: COMPLETED